Skip to main content
Triangle logo TriangleGet started

Talazoparib with enzalutamide (NCT06844383)

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide: a one-minute explainerNCT068443831 min

Talazoparib with enzalutamide trial for Prostate Cancer (Adenocarcinoma) (NCT06844383). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with metastatic castration-resistant prostate cancer, an eligible DNA-repair mutation, and progression on abiraterone or darolutamide. Prior PARP inhibitors or prostate-cancer platinum chemotherapy are excluded.

The idea: talazoparib blocks DNA repair; enzalutamide blocks androgen-receptor signaling. Random assignment compares daily oral talazoparib alone with talazoparib plus enzalutamide. Talazoparib doses differ between arms. Medical or surgical castration continues. Researchers compare time without progression on scans; previous-treatment limits also apply.

This phase 2 study plans 126 patients. Alicia Morgans leads at Dana-Farber in Boston; eight US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.